Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. (2nd November 2022)

• Record Type: Journal Article
• Authors: Mihaila, Radu; Ruhela, Dipali; Xu, Lifang; Joussef, Sandra; Geng, Xin; Shi, Jianxia; Kim, Andrea S.; Yares, Wendy; Furstoss, Kevin; Iverson, Kent
• Is Part Of: Expert opinion on biological therapy. Volume 22:Number 11(2022)
• Page Start: 1417
• Page End: 1428
• Publication Date: 2022-11-02
• Subjects: Comparability -- inclacumab -- monoclonal antibody -- P-selectin -- sickle cell disease -- vaso-occlusive crisis; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2143260
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Background: Inclacumab is a recombinant, fully human, immunoglobulin IgG4 monoclonal antibody that selectively binds to P-selectin. Initially discovered and developed by Roche through phase 2 clinical studies in peripheral arterial disease and coronary artery disease, inclacumab has been in-licensed by Global Blood Therapeutics (GBT) as a potential treatment to reduce the frequency of vaso-occlusive crises in individuals with sickle cell disease. Research design and methods: GBT sought to demonstrate the analytical comparability between material produced by Roche and material produced by GBT to ensure that no meaningful differences in identity, safety, purity, potency, or bioavailability exist between the GBT and Roche lots. Results: Inclacumab samples produced by GBT were found to be comparable to the Roche v0.2 inclacumab samples based on (1) comparable primary and higher-order structures; (2) comparable purity profiles; (3) comparable potency, in vitro functional activities, and in vivo plasma exposures and pharmacokinetic profiles; and (4) comparable degradation patterns and kinetics under forced degradation conditions. Conclusions: Based on the design of this comparability study and the results obtained, the US Food and Drug Administration approved the changes to the manufacturing process and gave clearance for GBT to proceed with phase 3 clinical trials.